1. Njei, B, Rotman, Y, Ditah, I, et al. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology. 2015; 61: 191–199.
Google Scholar | Crossref | Medline2. Global Burden of Disease Cancer Collaboration; Fitzmaurice C, Allen C, et al . Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the Global Burden of Disease Study. JAMA Oncol 2016; 3: 524–548.
Google Scholar3. Fujiwara, N, Friedman, SL, Goossens, N, et al. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol 2017; 68: 526–549.
Google Scholar | Medline4. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer . EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol 2012; 56: 908–943.
Google Scholar | Crossref | Medline | ISI5. Bruix, J, Sherman, M and American Association for the Study of Liver Diseases . Management of hepatocellular carcinoma: An update. Hepatology 2011; 53: 1020–1022.
Google Scholar | Crossref | Medline | ISI6. Worns, MA, Galle, PR. Hepatocellular carcinoma in 2017: Two large steps forward, one small step back. Nat Rev Gastroenterol Hepatol 2018; 15: 74–76.
Google Scholar | Crossref | Medline7. Chang, TS, Wu, YC, Tung, SY, et al. Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis. Am J Gastroenterol 2015; 110: 836–844.
Google Scholar | Crossref | Medline8. Song, PP, Xia, JF, Inagaki, Y, et al. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol 2016; 22: 262–274.
Google Scholar | Crossref | Medline9. Kinoshita, A, Onoda, H, Fushiya, N, et al. Staging systems for hepatocellular carcinoma: Current status and future perspectives. World J Hepatol 2015; 7: 406–424.
Google Scholar | Crossref | Medline10. Lai, Q, Iesari, S, Melandro, F, et al. The growing impact of alpha-fetoprotein in the field of liver transplantation for hepatocellular cancer: Time for a revolution. Transl Gastroenterol Hepatol 2017; 2: 72.
Google Scholar | Crossref11. Han, K, Tzimas, GN, Barkun, JS, et al. Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation. Can J Gastroenterol 2007; 21: 39–45.
Google Scholar | Crossref | Medline12. Vibert, E, Azoulay, D, Hoti, E, et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: A critical factor. Am J Transplant 2010; 10: 129–137.
Google Scholar | Crossref | Medline13. Dumitra, TC, Dumitra, S, Metrakos, PP, et al. Pretransplantation alpha-fetoprotein slope and Milan criteria: Strong predictors of hepatocellular carcinoma recurrence after transplantation. Transplantation 2013; 95: 228–233.
Google Scholar | Crossref | Medline14. Lai, Q, Avolio, AW, Graziadei, I, et al. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl 2013; 19: 1108–1118.
Google Scholar | Crossref | Medline15. Clavien, PA, Lesurtel, M, Bossuyt, PM, et al. Recommendations for liver transplantation for hepatocellular carcinoma: An international consensus conference report. Lancet Oncol 2012; 13: e11–e22.
Google Scholar | Crossref16. Heimbach, JK, Kulik, LM, Finn, R, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2017; 67: 358–380.
Google Scholar17. Weinmann, A, Koch, S, Niederle, IM, et al. Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: An analysis of 1066 cases of a German HCC Registry. J Clin Gastroenterol 2014; 48: 279–289.
Google Scholar | Crossref | Medline18. Llovet, JM, Bru, C, Bruix, J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 1999; 19: 329–338.
Google Scholar | Crossref | Medline | ISI19. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: The Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28: 751–755.
Google Scholar | Crossref | Medline | ISI20. Toyoda, H, Kumada, T, Osaki, Y, et al. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin Gastroenterol Hepatol 2006; 4: 1528–1536.
Google Scholar21. Johnson, PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 2001; 5: 145–159.
Google Scholar | Crossref | Medline22. Forner, A, Reig, M, Bruix, J. Alpha-fetoprotein for hepatocellular carcinoma diagnosis: The demise of a brilliant star. Gastroenterology 2009; 137: 26–29.
Google Scholar | Crossref | Medline23. Omata, M, Cheng, AL, Kokudo, N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update. Hepatol Int 2017; 11: 317–370.
Google Scholar | Crossref | Medline24. Mazzaferro, V, Bhoori, S, Sposito, C, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: An evidence-based analysis of 15 years of experience. Liver Transpl 2011; 17(Suppl. 2): S44–S57.
Google Scholar | Crossref | Medline | ISI25. Mehta, N, Dodge, JL, Goel, A, et al. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: Implications for the current organ allocation policy. Liver Transpl 2013; 19: 1343–1353.
Google Scholar | Crossref | Medline26. Lai, Q, Avolio, AW, Manzia, TM, et al. Combination of biological and morphological parameters for the selection of patients with hepatocellular carcinoma waiting for liver transplantation. Clin Transpl 2012; 26: E125–E131.
Google Scholar | Crossref27. Stuart, KE, Anand, AJ, Jenkins, RL. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 1996; 77: 2217–2222.
Google Scholar | Crossref | Medline | ISI28. De Carlis, L, Giacomoni, A, Pirotta, V, et al. Surgical treatment of hepatocellular cancer in the era of hepatic transplantation. J Am Coll Surgeons 2003; 196: 887–897.
Google Scholar | Crossref | Medline29. Yao, FY, Ferrell, L, Bass, NM, et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394–1403.
Google Scholar | Crossref | Medline | ISI30. Figueras, J, Ibanez, L, Ramos, E, et al. Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: Results of a multicenter study. Liver Transpl 2001; 7: 877–883.
Google Scholar | Crossref | Medline31. Shetty, K, Timmins, K, Brensinger, C, et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 2004; 10: 911–918.
Google Scholar | Crossref | Medline32. Kitai, S, Kudo, M, Minami, Y, et al. Validation of a new prognostic staging system for hepatocellular carcinoma: A comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score. Oncology 2008; 75(Suppl. 1): 83–90.
Google Scholar | Crossref | Medline33. Berhane, S, Toyoda, H, Tada, T, et al. Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. Clin Gastroenterol Hepatol 2016; 14: 875–886.e6.
Google Scholar | Crossref | Medline